NRX treding towards retest of last resistance at 1.09
Showcasing the recent developments of TSXV:NRX , will be upgrading on the OTC very soon which should help the volume. Currently holding the 200MA.
Biotech
VINC Biotech Penny Stock Followup Swing TradesVINC was a penny stock and is now in the near penny category as this biotech stock has had
a great run in the past 10 days. On the 30 minute chart, 225 shares are bought at low prices
and 125 shares are sold for profit with 100 shares still running as the momentum slows.
Overall, the trades where profitable averaging 12% daily in an average trade of 4.5 days.
Time and effort in the trade were minimal as the price action was monitored by alerts
and notifications as to price to moving average and moving average to moving average crosses
as well as dips and peaks of RSI under 40 or over 70 to notify for potential buys or sells
in this zig-zag strategy which intended to optimize profit and minimize time and effort
in trading.
Wuxi Biologics (2269): Incredible long-term opportunity! Wuxi Biologics (2269): HKEX:2269
Wuxi Biologics, a Chinese biotech research company listed on the Hong Kong Stock Exchange, presents a complex investment scenario. It's crucial to note we're dealing with the Hong Kong Dollar, not the US dollar. The comprehensive analysis on the weekly chart suggests that since June 2021, the company has been undergoing a correction defense scenario. This downturn has been so pronounced that the stock might need to reach its origin point at 8.56 HKD to complete the correction cycle of Wave 2 through Wave (Y) in blue. This process is expected to involve an initial surge followed by a downturn.
While there's potential for early position building, the decision to do so carries its uncertainties, given regulatory concerns and the stock's unpredictable future. Our strategy is to remain patient, observing how events unfold. Even with a 30% stop-loss threshold, which practically doesn't apply given the upside, we anticipate a minimum 2600% movement for Wave III in red, with the potential to reach an extraordinary 6000% at maximum. Such figures outline the vast upward trajectory expected, not just through Wave 3 but also with an ensuing Wave V.
Therefore, we are comfortable waiting and watching for the right entry point. Even if we decide to enter the market at a later stage, we expect that Wuxi Biologics will still offer significant opportunities.
VINC a speculative biotech penny stock LONGVINC went from 1.5 to 3.0 in less than three hours with 12X relative volume in the afternoon
after a month of a slow climb from a news release that really did not amount to much. Insiders
are 25% of the shareholders and that may be the story here. This could be manipulation at its
finest. I have to wonder how many insiders bought how many shares and when the rug pull.
This is a high tight bull flag pattern which typically results in another leg higher of the same
magnitude. I suppose that is in clean trading without any manipulation.
If this takes off again it might be worth trying with a small position so long as the trader
can hit a button to close the full position when the sudden reversal occurs. I will trade
this long with a group of moving averages to make alerts for crossing lines and slopes
levelling out and see if it can go anywhere.
CERUS Long idea on watchPositive news on phase 3 trials.
Possible US food & drug admin application next year 2025
8.5 times the usual 20 daily volume average.
Red to green reversal.
This all points towards likely higher prices. If their application next year gets approved expect a monster move. Investors will likely try to front run this.
Quantum-Si, biotech stock near pivotQuantum-Si NASDAQ:QSI , develops access to the proteome with single-molecule analysis and democratizing to researchers & clinicians
Also, "is the world’s first-to-market provider of protein sequencing instruments with core technology based on proprietary time-domain sequencing that enables resolution of amino acids during experiments".- Ark Invest
The stock is near finalizing its bottoming process with a pivot buy at $2.50
The Biotech ETF AMEX:XBI already broke out so NASDAQ:QSI is no leader, but still is a good set up.
IBB Biotech is due for a runAt some point there will be a boom biotechnology stocks. They haven't done much in the past ten years. I believe IBB will pass 250 within the decade. However, if the market remains stable, without any 20%+ corrections, I think IBB hits 250 to 300 in the next year
💊 Blueprint Medicines: Positive Momentum and Growth Prospects! 📊 Analysis NASDAQ:BPMC :
Financial Performance: 90% YoY growth in net-product revenues from U.S. sales of Ayvakit, a drug for certain cancers.
Market Prospects: Positive market response to Ayvakit's unique clinical profile.
CEO's Confidence: CEO's confidence in the company's future contributes to its momentum.
📈 Bullish Sentiment:
Entry Range: Suggested entry above the $83.00-$84.00 range.
Upside Target: Aiming for an upside in the $120.00-$125.00 range.
🌐 Note: Monitor BPMC's ongoing developments and market performance! 📊💹 #BPMC #Biotech #BullishSentiment 💊📈
Nutrix Therapeutics ( NRIX) has momentum for earnings LONGNRIX , on the 15 minute chart is experiencing increase volatility and volume now two
days out from its earnings report. It printed a "big ass" green engulfing candle to finish the
week. The MACD with zero lag shows a bullish inflection in the lines
On the daily chart, price fell about 25% in 2023. earnings have been both line beats but
the negative cash flow remains as a challenge. The volume and volatility show both are
heightened in the pre-earnings run- up. . This is a risky earnings
play, NRIX does not yet make money like many other young biotechnology companies trying to
grow However, because it lost less than forecasted, buyer interest has increased. There is
an absence of any options volume and so illiquidity prevents consideration of options
trading. I suspect a long trade in shares may gain to $14 targeting the pivot highs of
April 23 and November 22 for projected gain upside of about 65% ( stop loss of 2.5%)
If earnings disappoint trader expectations and price fades I will stop out with a loss of about
2.5% This makes this long swing trade a projected 2.5 /65 a R:r of 25 which validates it as
a conservative trade if taking only 5% or less of buyer power applied to the risk. Biotechnology
is expected to be one of the hottest subsectors of 2024. This could be one of them.
LABU / LABD Ratio Anchored VWAP over /under LABU LONGOn the weekly chart a LABU / LABD ratio is plotted with anchored VWAP bands and a volume
profile overlaid. I wanted to analyze this to affirm the highest of prospects for the
Biotechnology sector for 2024. LABU is triple leveraged Up while LABD is the inverse Down.
A good unleveraged biotech ETF is XBI. The chart shows LABU in a VWAP band and breakout
through the hohg volume area and then over it beginning early November. Unusually high
relative volume and volatility ramped up about the same time.
I readily conclude that LABU is the buy right now with the ratio rising. It is a low beat ETF
with good range due to the leveraging and high forecasts for 2024. I will make buys on
LABU at regular intervals on a 60-120 minute time frame looking for the weekly lows.
I will set an alert for a falling ratio on the 3H to daily chart to assess should the supertrend
fade. I believe that this will be a safe low risk swing long trade.
XBI Consolidating Just Below Major PivotXBI, the S&Ps Biotech ETF has been ranging nicely just below a major pivot that has acted as resistance for over two years. Bounced off the 20 EMA on the daily and made a beautiful candle on Friday. Anything that happens below $95 must be taken with a grain of salt, but it looks like it wants to breakout and flip that resistance pivot to support.
NBIX Biotechnology / Pharmaceutical Pre-earnings LONGNeurocrine Biosciences, a mid cap pharmaceutical firm is up for earnings on February 7th.
Investor and trader interest seems to be moderately increasing in the past week. The combined
MACD / RSI indicator is bullish. This looks good for a longtrade to be taken in the premarket
before 7:45 AM as earnings report at 8:00
RYTM Biotech Penny Anti-Obesity LONGRYTM did a 120% run in November and December and then pivoted to start the year. It competes
in the anti-obesity drug space which is all the rage right now and has snack food manufactures
freaking out. The retrace was a shallow one in a sign of strength finding support at the 0.382
retracement level and then pivoting into a reversal in the past week. The dual TF RSI shows
the resurgence of bullish momentum. Earnings were okay, but not great. An FDA approval to add
to the mix of meds and lower their price in the competition may send RHYTHM into
launch mode. RYTM did 10% today such is the life of highly volatile penny stocks in what is
considered to be the likely hottest sector of the year. I will look toward OTM call options
for February 16th presently priced at about $200 per contract and a couple of shares shorted
to provide some hedging. Looking for 100% in 2-3 weeks. Will close 1/2 the position a few days
before upcoming earnings.
"NBIX Stock Breaks All-Time Highs, Strong Buy Opportunity!"NBIX Stock Breaks All-Time Highs: A Strong Buy Opportunity Emerges
Neurocrine Biosciences Inc. (NBIX) is currently making waves in the stock market as it breaks out of its all-time highs, signaling a promising opportunity for investors. After 14 years of steady upward momentum and price consolidation, NBIX appears poised for further growth, with technical indicators suggesting a bullish trend ahead.
The recent surge in NBIX's stock price comes on the heels of strong performance and positive sentiment surrounding the company's products and pipeline. With a focus on innovative treatments for neurological and endocrine disorders, Neurocrine Biosciences has established itself as a leader in the biopharmaceutical industry, attracting investors seeking exposure to high-growth sectors.
Technical analysis reveals that NBIX's current breakout is accompanied by the formation of a bull flag pattern, a bullish continuation pattern that often precedes further upward movement. This consolidation phase following a prolonged uptrend suggests that NBIX may be gearing up for another leg higher, providing an attractive entry point for investors.
To capitalize on this potential opportunity, traders are advised to monitor the 4-hour time frame closely, watching for confirmation of the breakout and additional upside momentum. A sustained move above the current resistance levels could signal further strength in NBIX's stock price, potentially leading to a retest of its previous all-time highs.
Investors considering a position in NBIX should also keep an eye on key support levels and market dynamics, as volatility in the broader market could impact the stock's trajectory. However, with a strong track record of growth and a robust pipeline of innovative therapies, NBIX appears well-positioned to weather any short-term fluctuations and deliver long-term value to shareholders.
In conclusion, Neurocrine Biosciences Inc. is breaking out of its all-time highs, presenting a compelling buying opportunity for investors. With 14 years of upward momentum behind it and a bullish pattern forming, NBIX looks poised for further growth in the coming weeks and months. By monitoring the 4-hour time frame and remaining vigilant for additional breakouts, investors can position themselves to capitalize on the potential upside in NBIX's stock price.
$XBI: Looking For A Probe Below 87.5Both biotech ETF's AMEX:XBI and NASDAQ:IBB are showing tremendous weakness in the face of a strong market. I suspect that when the market is ready to pullback it may take this a little lower especially in the face of a strong TVC:DXY / Dollar Index. Good luck traders!
CNTB to Climb to $2Looking at the micro data, we have an uptrend where we're following along the rising bottom.
Looking a bit further out, we can see we're in a bullish wedge.
General trends say that this will come up, and the company will have only good news about their trials progressing which will drive the price higher.
Very near to $2 by the end of February, and we could very well see $4 by the end of Summer.
NASDAQ:CNTB
MGNX a biotech company gets new "Outperform" LONGMGNX as a biotech company makes antibodies against certain cancers. The antibody is tagged to
chemotherapy molecules and then heads off looking for cancer cells to which it has a strong
affinity. So much for the science. MGNX just got upgraded and the new target is $ 16.00 about
25% upside. Biotech and healthcare are projected hot sectors this year.
On the 15 minute chart price jumped about 12% in the past week and bounced down toward
the anchored mean VWAP and is well situated for a long entry. the dual TF RSI indicator
shows both lines crossing the 50 level in early bullish momentum off the bounce.
It is continually hitting new past year highs at a great trend angle and is on pace to hit 400% for
an annual return. There is no option play here as the volume is minimal and liquidity is absent.
The all-time high is about $32 so there is plenty of room above the analyst's target over the long
term. Price has moved 12X the S & P YTD certainly a sign of relative strength.
Strong bullish case for $LABDCan see this at $15.00 given that is where most shares are currently held, according to FRVP; this means there will likely be little downwards price pressure until then. Biotech is generally bearish outside of select, short-lived bull runs - this, in my opinion, creates an opportunity for sentiment arbitrage and is my reasoning for the trade (short term/long term outlooks are both bearish)
IBB - iShares Biotech EFT - SHORT (Wyckoff Redistribution)IBB looks to be in a Wyckoff Redistribution phase, with UTAD emerging currently.
On a larger time frame, looks as though a weekly H&S patter forming with the re-distribution section acting as the right shoulder.
My price target is $57, in line with the 1.618 fib extension.
Bluebird Bio (NASDAQ: BLUE) Posing Strong Bearish TrendBLUE is currently trading above its 50-day and 200-day simple moving averages (SMA), indicating a bullish trend. However, the 50-day SMA is below the 200-day SMA, forming a death cross pattern, which is a bearish signal.
The 20-day exponential moving average (EMA) is also above the current price, acting as a resistance level. A break above the 20-day EMA could signal a continuation of the uptrend, while a break below the 50-day SMA could signal a reversal of the trend.
Earnings and Revenue: The earnings per share (EPS) of BLUE is expected to decline by 37.50% in the current quarter (Dec 2023) and increase by 333.30% in the next quarter (Mar 2024). The EPS for the current year (2023) is estimated to be -$11.7, which is a 59.10% decrease from the previous year (2022). The EPS for the next year (2024) is projected to be -$8.6, which is an 26.50% increase from the current year2. The revenue of BLUE is expected to decrease by 3.10% in the current quarter (Dec 2023) and increase by 9.00% in the next quarter (Mar 2024). The revenue for the current year (2023) is estimated to be $289.2 million, which is a 0.80% decrease from the previous year (2022). The revenue for the next year (2024) is forecasted to be $313.6 million, which is a 8.40% increase from the current year.
The technical analysis of BLUE shows that the stock is in a mixed trend, with some bullish and bearish signals. The stock is also facing low volatility and uncertain momentum. The earnings and revenue estimates suggest that the company is going through a challenging period, but might recover in the future.
BIotech sector seems to be starting a new bullish phaseAccording to the CEO of NVDA, the next big revolution is coming into biotech. Biology will be engineered and therefore will compound exponentially. Now might be a good time to enter this field.
SRPT Sarepta Therapeutics Potential Buyout SoonIf you haven`t bought SRPT here:
Then you need to know that there is a Massive catalyst coming!
Sarepta Therapeutics is going to announce Duchenne muscular dystrophy Phase 3 data for its SRP-9001-301 - (EMBARK) by mid November.
This week institutions bought calls worth more than $10Mil that SRPT Sarepta Therapeutics will trade above $135 by November 17.
Some even bought the $210 strike price!
They also have a big partnership with the giant Roche Holding AG (RHHBY).
I think SRPT Sarepta Therapeutics is well positioned for a potential takeover soon!
Looking forward to read your opinion about it.
NVTA Invitae Corporation All Time Low | Potential Buyout !Last year in Autumn we had this buyout rumor. I remember back then Exact Sciences said to approach Invitae about a potential merger.
Now, NVTA, Invitae Corporation, is trading at an all-time low, $0.62.
Some deals take one or two years to perfect, and we don't know what caused the recent price decrease.
Sometimes this happens before an announcement.
Today, Invitae announced the appointment of finance veteran Ana Schrank as CFO; she spent more than 20 years at McKesson Corporation where she held leadership roles. Could this CFO be hired ahead of a takeover?! We don't know!
But with an RSI of 19.34 and an all-time low, along with ARK Invest being the 2nd largest shareholder at an average price of $15.08,
I think this looks like a great buying opportunity!
Looking forward to read your opinion about it!
